A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Tvardi Therapeutics, Inc. ("Tvardi") , a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on ...